Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes

被引:82
作者
Redmon, J. Bruce [1 ]
Bertoni, Alain G. [2 ]
Connelly, Stephanie [3 ]
Feeney, Patricia A. [4 ]
Glasser, Stephen P. [5 ]
Glick, Henry [6 ]
Greenway, Frank [7 ]
Hesson, Louise A. [8 ]
Lawlor, Michael S. [9 ]
Montez, Maria [10 ]
Montgomery, Brenda [11 ,12 ]
机构
[1] Univ Minnesota, Sch Med, Dept Med, Div Endocrinol, Minneapolis, MN 55455 USA
[2] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA
[3] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA
[4] Wake Forest Univ, Dept Biostat, Winston Salem, NC 27109 USA
[5] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA
[6] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[7] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA
[8] Univ Penn, Weight & Eating Disorders Program, Philadelphia, PA 19104 USA
[9] Wake Forest Univ, Dept Econ, Winston Salem, NC 27109 USA
[10] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA
[11] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[12] Univ Washington, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
LIFE; MELLITUS; INSULIN; THERAPY;
D O I
10.2337/dc09-2090
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND METHODS-Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy. RESULTS-Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 +/- 1.8 for the ILI group and 3.6 +/- 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 +/- 1.6 medications at an estimated cost of $194/month. ILL participants at optimal care required fewer medications (3.2 +/- 1.7) at lower cost ($1.54/month) (P < 0.001). CONCLUSIONS-At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.
引用
收藏
页码:1153 / 1158
页数:6
相关论文
共 24 条
[1]   Standards of medical care in diabetes 2008 [J].
不详 .
DIABETES CARE, 2008, 31 :S12-S54
[2]   One hundred-pound weight losses with an intensive behavioral program: changes in risk factors in 118 patients with long-term follow-up [J].
Anderson, James W. ;
Conley, Shannon B. ;
Nicholas, Amy S. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 86 (02) :301-307
[3]  
[Anonymous], 1998, Obes Res, V6, p51S
[4]  
[Anonymous], 2006, Diab Vasc Dis Res
[5]  
[Anonymous], 2005, Global guideline for type 2 Diabetes. Clinical guideline task force
[6]   Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes [J].
Brancati, F ;
Charleston, J ;
Cheskin, L ;
Clark, J ;
DiGregorio-Celnik, D ;
Friedman-Donze, L ;
Rubin, R ;
Stewart, K ;
Bray, GA ;
DeLee, DG ;
Boss, KR ;
Greenway, FL ;
Lovejoy, JC ;
Ryan, DH ;
Williamson, DA ;
West, DS ;
DiLillo, V ;
Raczynski, JM ;
Lewis, CE ;
Oberman, A ;
Thomas, S ;
Nathan, DM ;
Horton, ES ;
Turgeon, H ;
Jackson, SD ;
Blackburn, GL ;
Delahanty, L ;
Steiner, B ;
Cagliero, E ;
Mantzoros, C ;
Hill, JO ;
Phillipp, J ;
Hamman, RF ;
Schwartz, R ;
Regensteiner, J ;
Van Dorsten, B ;
McDermott, MT ;
Dills, DG ;
Foreyt, JP ;
Reeves, RS ;
Pownell, HJ ;
Balasubramanyam, A ;
Jones, PH ;
Saad, MF ;
Jinagouda, S ;
Chiu, K ;
Morales, L ;
Ghazarian, S ;
Navarrete, G ;
Iqbal, N .
CONTROLLED CLINICAL TRIALS, 2003, 24 (05) :610-628
[7]  
Buse JB, 2007, DIABETES CARE, V30, P162, DOI [10.2337/dc07-9917, 10.1161/CIRCULATIONAHA.106.179294]
[8]   MEDICATION COST SAVINGS ASSOCIATED WITH WEIGHT-LOSS FOR OBESE NON-INSULIN-DEPENDENT DIABETIC MEN AND WOMEN [J].
COLLINS, RW ;
ANDERSON, JW .
PREVENTIVE MEDICINE, 1995, 24 (04) :369-374
[9]   A systematic review of adherence with medications for diabetes [J].
Cramer, JA .
DIABETES CARE, 2004, 27 (05) :1218-1224
[10]   Triple therapy - Definitions, application, and treating to target [J].
Davidson, MB .
DIABETES CARE, 2004, 27 (07) :1834-1835